Otsuka, Bristol Seek Quick Win On Abilify Fail-To-Warn Claims
Otsuka Pharmaceutical Co. Ltd. and Bristol-Myers Squibb Co. are looking to narrow one of three cases set for trial in multidistrict litigation over side effects of the antipsychotic drug Abilify, arguing...To view the full article, register now.
Already a subscriber? Click here to view full article